News >

Ofatumumab Combo Falls Short in Indolent Non-Hodgkin Lymphoma

Jason M. Broderick @jasoncology
Published: Thursday, May 24, 2018

Jan van de Winkel, PhD

Jan van de Winkel, PhD
Adding ofatumumab (Arzerra) to bendamustine (Treanda) failed to improve progression-free survival (PFS) in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) who did not respond to rituximab (Rituxan) monotherapy or a rituximab-containing regimen, missing the primary endpoint of the phase III COMPLEMENT A+B trial. 

The ORRs in the follicular lymphoma, SLL, and marginal zone lymphoma groups were 41%, 68%, and 33%, respectively. The median duration of response was 9.9 months. At a median follow-up of 11.5 months, the median OS in the entire iNHL population was 18.4 months and the median PFS was 8.4 months.


  1. Noy A, de Vos S. Thieblemont C, et al. Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study. Presented at: ASH 2016 Annual Meeting. Abstract 1213.
  2. Verastem submits new drug application to US FDA for duvelisib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. Verastem. Published February 7, 2018, Accessed April 9, 2018.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication